Emerging DUBTACs Highlight Vicinitas Therapeutics as a specialized biotech focusing on Deubiquitinase Targeting Chimeras (DUBTACs) to address previously undruggable proteins, presenting a sales opportunity for research collaborations, licensing discussions, or sponsored programs with larger pharma partners seeking next-generation modalities.

Strategic Spinout Heritage Leverage the academic-industry collaboration origin (Novartis Institutes for BioMedical Research and UC Berkeley) to position partnerships around translational science, joint development ventures, and access to a network of academia-led innovation that can accelerate co-development deals.

Early-Stage Funding Signals With current revenue in the zero-to-one million range and a lean team, pursue discussions around strategic investments, non-dilutive funding, and milestone-based partnerships that provide capital for early-stage preclinical and platform expansion without heavy upfront risk.

Targeted Protein Stability Identify potential customers and collaborators in oncology and monogenic disease spaces where stabilization of tumor suppressors or other degraded proteins could create new therapeutic avenues, offering opportunities for research collaborations, grant-supported projects, and co-development licensing.

Technology and Data Readiness Position Vicinitas as a partner for technology-enabled discovery programs, offering access to their DUBTAC platform alongside service-based collaborations, with emphasis on rapid target engagement strategies, assay development, and shared IP opportunities to attract big pharma interest.